Next Article in Journal
IGF-1 Antibody Prolongs the Effective Duration Time of Botulinum Toxin in Decreasing Muscle Strength
Next Article in Special Issue
Neuroprotective Effect of Melatonin: A Novel Therapy against Perinatal Hypoxia-Ischemia
Previous Article in Journal
Ribonucleoprotein Complexes That Control Circadian Clocks
Previous Article in Special Issue
New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2013, 14(5), 9037-9050;

Role of Melatonin in Schizophrenia

Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, 38071 La Laguna, Spain
Psychiatric Consultancy SC, 38001 Santa Cruz de Tenerife, Spain
Department of Physiology, School of Medicine, University of La Laguna, 38071 La Laguna, Spain
Author to whom correspondence should be addressed.
Received: 19 February 2013 / Revised: 9 April 2013 / Accepted: 10 April 2013 / Published: 25 April 2013
(This article belongs to the Special Issue Advances in the Research of Melatonin)
Full-Text   |   PDF [195 KB, uploaded 19 June 2014]


Schizophrenia is a chronic mental disease that disturbs several cognitive functions, such as memory, thought, perception and volition. Schizophrenia’s biological etiology is multifactorial and is still under investigation. Melatonin has been involved in schizophrenia since the first decades of the twentieth century. Research into melatonin regarding schizophrenia has followed two different approaches. The first approach is related to the use of melatonin as a biological marker. The second approach deals with the clinical applications of melatonin as a drug treatment. In this paper, both aspects of melatonin application are reviewed. Its clinical use in schizophrenia is emphasized. View Full-Text
Keywords: melatonin; schizophrenia; biological marker; therapeutic agent melatonin; schizophrenia; biological marker; therapeutic agent
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Morera-Fumero, A.L.; Abreu-Gonzalez, P. Role of Melatonin in Schizophrenia. Int. J. Mol. Sci. 2013, 14, 9037-9050.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top